微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 27.32% | -17.22% | -6.67% | 120/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 29.27% | -9.8% | 7.93% | 116/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 27.12% | -13.67% | -22.6% | 121/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 35.04% | 7.44% | 6.17% | 104/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 33.01% | 3.54% | 1.7% | 110/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 32.45% | 9.96% | 3.3% | 110/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 31.42% | -13.32% | -3.67% | 109/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 32.61% | 5.64% | 2.31% | 116/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 31.88% | -1.86% | 8.01% | 114/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 29.51% | -2.73% | -18.57% | 118/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.24% | 15.58% | 17.4% | 103/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 30.87% | -23% | -4.95% | 120/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 32.48% | -20.5% | 7.04% | 112/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 30.34% | -28.2% | -3.23% | 119/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 31.36% | -22.56% | -21.8% | 116/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 40.1% | 7.51% | -1.86% | 103/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 40.85% | 10.63% | -3.32% | 95/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 42.26% | 13.97% | 4.37% | 94/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 40.49% | 15.75% | 8.57% | 92/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 37.29% | 2.31% | 0.99% | 113/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 36.93% | -3.07% | -0.41% | 100/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 37.08% | -3.43% | 6% | 109/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 34.98% | -0.49% | -4.04% | 95/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 36.45% | -4.94% | -4.31% | 111/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 38.09% | 1.88% | -0.78% | 91/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 38.4% | 5.52% | 9.22% | 98/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 35.15% | -7.54% | -8.33% | 89/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 38.35% | 17.76% | 2.55% | 101/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 37.39% | 26.18% | 2.77% | 81/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 36.39% | 31.59% | -4.29% | 86/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 38.02% | 43.03% | 16.75% | 78/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 32.56% | -4.43% | 9.89% | 108/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 29.63% | -12.24% | 7.17% | 87/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.65% | -22.99% | 4.03% | 95/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 26.58% | -25.05% | -21.99% | 90/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 34.07% | -9.05% | 0.91% | 90/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 33.77% | 2% | -5.96% | 69/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 35.91% | 5.08% | 1.26% | 72/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 35.46% | 2% | -5.34% | 59/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 37.46% | 13.74% | 13.74% | 72/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |